Pfizer's 2026 Outlook Reflects Cautious Growth and Long-Term Investment
Originally Published 26 days ago — by Investor's Business Daily
Pfizer's stock dropped over 5% after missing Wall Street earnings forecasts due to acquisitions and a cautious outlook, amid concerns over patent expirations for key products and hopes for future growth from new drugs and acquisitions like Seagen.